Paul Tudor Jones’s Tarsus Pharmaceuticals TARS Stock Holding History

Paul Tudor Jones’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$601K	Buy	+9,541	New	+$610K	﹤0.01%	2730
2026 Q1	–	Sell	-22,704	Closed	-$1.86M	–	4255
2025 Q4	$1.86M	Buy	+22,704	New	+$1.7M	﹤0.01%	1856
2025 Q1	–	Sell	-13,880	Closed	-$769K	–	3661
2024 Q4	$769K	Buy	+13,880	New	+$630K	﹤0.01%	1916
2024 Q2	–	Sell	-18,696	Closed	-$680K	–	2786
2024 Q1	$680K	Buy	+18,696	New	+$550K	﹤0.01%	1513
2023 Q4	–	Sell	-50,000	Closed	-$889K	–	2887
2023 Q3	$889K	Buy	+50,000	New	+$885K	0.01%	1361

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Paul Tudor Jones's TARS Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 9,541 shares worth $601K. The stake represents ﹤0.01% of the portfolio and ranks #2730 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in TARS as recently as Q4 2025.

Paul Tudor Jones first reported a position in TARS in Q3 2023 and has held it in 5 quarters since. The position peaked at $1.86M in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Paul Tudor Jones held 9,541 shares of Tarsus Pharmaceuticals worth $601K as of Q2 2026.
Tarsus Pharmaceuticals was a new Paul Tudor Jones position in Q2 2026.
Tarsus Pharmaceuticals made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2730 holding.
Paul Tudor Jones first reported a position in Tarsus Pharmaceuticals in Q3 2023 and has held it in 5 quarters since.
Paul Tudor Jones's Tarsus Pharmaceuticals position peaked at $1.86M in Q4 2025.
256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.